Prelude Therapeutics Stock Forward View - Triple Exponential Smoothing
| PRLD Stock | USD 1.90 0.07 3.55% |
Prelude Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Prelude Therapeutics stock prices and determine the direction of Prelude Therapeutics's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Prelude Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time, the value of RSI of Prelude Therapeutics' share price is approaching 48 indicating that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Prelude Therapeutics, making its price go up or down. Momentum 48
Impartial
Oversold | Overbought |
Using Prelude Therapeutics hype-based prediction, you can estimate the value of Prelude Therapeutics from the perspective of Prelude Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Triple Exponential Smoothing forecasted value of Prelude Therapeutics on the next trading day is expected to be 1.84 with a mean absolute deviation of 0.24 and the sum of the absolute errors of 14.06. Prelude Therapeutics after-hype prediction price | USD 1.9 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Prelude Therapeutics to cross-verify your projections. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.Prelude Therapeutics Additional Predictive Modules
Most predictive techniques to examine Prelude price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Prelude using various technical indicators. When you analyze Prelude charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Prelude Therapeutics Triple Exponential Smoothing Price Forecast For the 30th of January
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Prelude Therapeutics on the next trading day is expected to be 1.84 with a mean absolute deviation of 0.24, mean absolute percentage error of 0.40, and the sum of the absolute errors of 14.06.Please note that although there have been many attempts to predict Prelude Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Prelude Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Prelude Therapeutics Stock Forecast Pattern
| Backtest Prelude Therapeutics | Prelude Therapeutics Price Prediction | Buy or Sell Advice |
Prelude Therapeutics Forecasted Value
In the context of forecasting Prelude Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Prelude Therapeutics' downside and upside margins for the forecasting period are 0.02 and 24.15, respectively. We have considered Prelude Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Prelude Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Prelude Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 0.0771 |
| MAD | Mean absolute deviation | 0.2384 |
| MAPE | Mean absolute percentage error | 0.1285 |
| SAE | Sum of the absolute errors | 14.0648 |
Predictive Modules for Prelude Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prelude Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Prelude Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Prelude Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Prelude Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Prelude Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Prelude Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Prelude Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Prelude Therapeutics' historical news coverage. Prelude Therapeutics' after-hype downside and upside margins for the prediction period are 0.10 and 24.21, respectively. We have considered Prelude Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Prelude Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Prelude Therapeutics is based on 3 months time horizon.
Prelude Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Prelude Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Prelude Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Prelude Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.04 | 22.31 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.90 | 1.90 | 0.00 |
|
Prelude Therapeutics Hype Timeline
Prelude Therapeutics is at this time traded for 1.90. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Prelude is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is at this time at 2.04%. %. The volatility of related hype on Prelude Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 1.90. About 54.0% of the company shares are owned by institutional investors. The book value of Prelude Therapeutics was at this time reported as 0.77. The company recorded a loss per share of 1.47. Prelude Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be within a week. Check out Historical Fundamental Analysis of Prelude Therapeutics to cross-verify your projections. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.Prelude Therapeutics Related Hype Analysis
Having access to credible news sources related to Prelude Therapeutics' direct competition is more important than ever and may enhance your ability to predict Prelude Therapeutics' future price movements. Getting to know how Prelude Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Prelude Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PYXS | Pyxis Oncology | 0.00 | 0 per month | 0.00 | (0.08) | 17.05 | (15.41) | 70.66 | |
| OBIO | Orchestra BioMed Holdings | 0.00 | 0 per month | 3.94 | (0.01) | 8.47 | (5.98) | 19.35 | |
| ENTA | Enanta Pharmaceuticals | 0.00 | 0 per month | 2.71 | 0.08 | 5.67 | (3.59) | 15.79 | |
| CRBU | Caribou Biosciences | 0.00 | 0 per month | 0.00 | (0.19) | 6.86 | (6.41) | 20.16 | |
| IVA | Inventiva Sa | 0.00 | 0 per month | 3.62 | 0.15 | 9.41 | (6.05) | 18.43 | |
| TNYA | Tenaya Therapeutics | 0.00 | 0 per month | 0.00 | (0.10) | 9.02 | (8.57) | 49.22 | |
| AVTX | Avalo Therapeutics | 0.00 | 0 per month | 0.00 | (0.05) | 6.64 | (6.28) | 23.40 | |
| EPRX | Eupraxia Pharmaceuticals Common | 0.00 | 0 per month | 2.80 | 0.17 | 6.98 | (4.46) | 24.61 | |
| IMRX | Immuneering Corp | 0.00 | 0 per month | 0.00 | (0.04) | 8.12 | (5.64) | 67.18 | |
| FHTX | Foghorn Therapeutics | 0.00 | 0 per month | 4.33 | 0.09 | 9.16 | (5.56) | 31.12 |
Other Forecasting Options for Prelude Therapeutics
For every potential investor in Prelude, whether a beginner or expert, Prelude Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Prelude Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Prelude. Basic forecasting techniques help filter out the noise by identifying Prelude Therapeutics' price trends.Prelude Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prelude Therapeutics stock to make a market-neutral strategy. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Prelude Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Prelude Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Prelude Therapeutics shares will generate the highest return on investment. By undertsting and applying Prelude Therapeutics stock market strength indicators, traders can identify Prelude Therapeutics entry and exit signals to maximize returns.
| Accumulation Distribution | 109134.0 | |||
| Daily Balance Of Power | (0.28) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 1.92 | |||
| Day Typical Price | 1.92 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.07) | |||
| Relative Strength Index | 48.05 |
Prelude Therapeutics Risk Indicators
The analysis of Prelude Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Prelude Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting prelude stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 9.81 | |||
| Semi Deviation | 11.86 | |||
| Standard Deviation | 22.31 | |||
| Variance | 497.61 | |||
| Downside Variance | 197.18 | |||
| Semi Variance | 140.72 | |||
| Expected Short fall | (11.18) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Prelude Therapeutics
The number of cover stories for Prelude Therapeutics depends on current market conditions and Prelude Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Prelude Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Prelude Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Prelude Therapeutics Short Properties
Prelude Therapeutics' future price predictability will typically decrease when Prelude Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Prelude Therapeutics often depends not only on the future outlook of the potential Prelude Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prelude Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 75.8 M | |
| Cash And Short Term Investments | 133.6 M |
Check out Historical Fundamental Analysis of Prelude Therapeutics to cross-verify your projections. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Stock sector continue expanding? Could Prelude diversify its offerings? Factors like these will boost the valuation of Prelude Therapeutics. Anticipated expansion of Prelude directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Prelude Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prelude Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prelude Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prelude Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.